Publikationen von Udo Reichl
Alle Typen
Konferenzbeitrag (36)
321.
Konferenzbeitrag
Investigations of pellet forming microorganisms by means of an image processing system. In: 5th European Congress on Biotechnology: Vol. 2, S. 1166 - 1170 (Hg. Christiansen, C.; Munck, L.; Villadsen, J.). 5th European Congress on Biotechnology, Copenhagen, Denmark, 08. Juli 1990 - 13. Juli 1990. Munksgaard, Copenhagen (1990)
322.
Konferenzbeitrag
Early growth of Streptomyces in submerged culture. In: 8th DECHEMA annual meeting of biotechnologists, S. 825 - 828 (Hg. Behrens, D.; Krämer, P.). 8th DECHEMA annual meeting of biotechnologists, Frankfurt am Main, Germany, 28. Mai 1990 - 30. Mai 1990. VCH, Weinheim (1990)
323.
Konferenzbeitrag
3A (Hg. Behrens, D.). 7. Jahrestagung der Biotechnologen, Frankfurt am Main, Germany, 01. Juni 1989 - 02. Juni 1989. VCH, Weinheim (1989)
Use of an image processing system for investigation of the morphology of filamentously growing microorganisms. In: 7th DECHEMA annual meeting of biotechnologists, Bd. Meeting Abstract (45)
324.
Meeting Abstract
53 (2) Special Issue: SI Aufl., P376. Joint Conference of the Société Française d'Immunologie (SFI) and the Deutsche Gesellschaft für Immunologie (DGfI), Strasbourg (France), 26. September 2023. Wiley-VCH, Weinheim (2023)
Adjuvanted SARS-CoV-2 spike protein vaccination with altered glycosylation elicits improved TH1 humoral and cellular immunity in mice. In European Journal of Immunology, 325.
Meeting Abstract
Producing viruses in orbit: Current developments for orbital shaken viral vaccine manufacturing. In Proceedings Vaccine Technology VIII, 54. Vaccine Technology VIII, Sitges (Spain), 12. Juni 2022 - 17. Juni 2022. (2022)
326.
Meeting Abstract
Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processes. In Proceedings Vaccine Technology VIII, 60. Vaccine Technology VIII, Sitges (Spain), 12. Juni 2022 - 17. Juni 2022. (2022)
327.
Meeting Abstract
Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. In Proceedings Single-Use Technologies V: Building the Future, 40. Single-Use Technologies V: Building the Future, Marseille, France, 20. März 2022 - 23. März 2022. (2022)
328.
Meeting Abstract
SARS-COV-2 production in a single-use scalable high cell density bioreactor. In Proceedings Single-Use Technologies V: Building the Future, 29. Single-Use Technologies V: Building the Future, Marseille, France, 20. März 2022 - 23. März 2022. (2022)
329.
Meeting Abstract
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. In Proceedings Vaccine Technology VIII, 55. Vaccine Technology VIII, Sitges (Spain), 12. Juni 2022 - 17. Juni 2022. (2022)
330.
Meeting Abstract
Continuous mode of production for two classes of defective interfering influenza A virus particles as antiviral candidates. In Integrated Continuous Biomanufacturing IV, 76. Biomanufact IV, Ocean Edge Resort Brewster (Cape Cod), Massachusetts, USA , 06. Oktober 2019 - 10. Oktober 2019. (2019)
331.
Meeting Abstract
A single-use chromatographic purification platform for viral gene transfer vectors & viral vaccines. In Proceedings Advancing Manufacture of Cell and Gene Therapies VI, 92. Advancing Manufacture of Cell and Gene Therapies VI, Loews Coronado Bay Hotel Coronado, California, USA, 27. Januar 2019 - 31. Januar 2019. (2019)
332.
Meeting Abstract
Highly efficient influenza virus production: A MDCK-based high-cell-density process. In Vaccine Technology VII, 13. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
333.
Meeting Abstract
Orbital shaken bioreactor for influenza A virus production in high cell density cultivations. In Vaccine Technology VII, 40. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
334.
Meeting Abstract
Continuous purification of cell culture-derived influenza A virus particles through pseudo- affinity membrane chromatography. In Vaccine Technology VII, 124. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
335.
Meeting Abstract
A new porcine suspension cell line (PBG.PK-21) provides efficient production for influenza and yellow fever vaccine viruses. In Vaccine Technology VII, 48. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
336.
Meeting Abstract
Single-cell analysis uncovers a novel influenza A virus-derived defective interfering particle for antiviral therapy. In Vaccine Technology VII, 133. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
337.
Meeting Abstract
Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a capture platform for vaccine candidates. In Vaccine Technology VII, 128. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
338.
Meeting Abstract
Flavivirus production in perfusion processes using the EB66® cell line. In Vaccine Technology VII, 80. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
339.
Meeting Abstract
Addressing the challenges of influenza virus-like particles purification. In Vaccine Technology VII, 57. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
340.
Meeting Abstract
Influenza virus capture using membrane chromatography: Improving selectivity by matrix design and pseudo-affinity ligand interactions. In Vaccine Technology VII, 75. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)